Isracann Biosciences Inc. (ISCNF)
| Market Cap | 177.00 -87.5% |
| Revenue (ttm) | n/a |
| Net Income | -3.47M |
| EPS | -0.02 |
| Shares Out | 176.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 114,283 |
| Open | 0.00001 |
| Previous Close | 0.000001 |
| Day's Range | 0.000001 - 0.00001 |
| 52-Week Range | 0.000001 - 0.0002 |
| Beta | 17.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Isracann Biosciences
Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel. The company also develops cultivation facilities. It exports its products to Germany. The company was formerly known as Atlas Blockchain Group Inc. and changed its name to Isracann Biosciences Inc. in October 2019. Isracann Biosciences Inc. was founded in 2010 and is headquartered in Vancouver, Canada. [Read more]
Full Company ProfileNews
CSE Bulletin: Delist - Isracann Biosciences Inc. (IPOT)
Toronto, Ontario--(Newsfile Corp. - le 4 septembre/September 2024) - The common shares of Isracann Biosciences Inc. will be delisted from the CSE at market close today, September 4, 2024. Isracann Bio...
Isracann Biosciences Provides Bi-Weekly Default Status Report
VANCOUVER, British Columbia, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) announces that further to its news release dated Septem...
Isracann Biosciences Announces Delay in Filing Annual Financial Statements
VANCOUVER, British Columbia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) announces that the filing of its audited annual financ...
Isracann Bioscience Facilitated Genetics Arrive in Israel
Partner Facility Now Growing Canadian Cannabis Strains Partner Facility Now Growing Canadian Cannabis Strains
Praesidio signs distribution agreement with Pure Integrative Pharmacy
VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health med...
Isracann Adds Super Bowl MVP and Mental Health Advocate Mark Rypien to Advisory Board
VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health medi...
Isracann Biosciences Announces Closing of First Tranche of $0.05 Unit Private Placement
VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that it has closed the first tra...
Isracann Biosciences Subsidiary Praesidio Health Submits NPNs to Health Canada
VANCOUVER, British Columbia, May 19, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health medic...
Isracann Biosciences Renews Leadership to Meet Changing Demands
VANCOUVER, British Columbia, April 15, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that further to its acquisition...
Isracann Biosciences Acquires Natural Health Medicine Developer and Appoints Natural Health Products Officers
VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that, further to the Company's ...
Isracann Biosciences Signs Definitive Agreement to Acquire Natural Health Medicine Developer
VANCOUVER, British Columbia, March 28, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that, further to the Company's ...
UPDATE - Isracann Signs LOI to Acquire Natural Health Medicine Developer
VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) a biosciences company focused on research...
Isracann Signs LOI to Acquire Natural Health Medicine Developer
VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) a biosciences company focused on researc...
Isracann Advises on Recent Activities and 2022 Outlook
VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becom...
Isracann Appoints Operational Expert Phil Floucault as CEO and Grants Options
VANCOUVER, British Columbia, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becomi...
Isracann Receives Foreign Owners License and Updates Israeli Cannabis Operations
License paves way for market penetration and growth opportunities License paves way for market penetration and growth opportunities
Isracann Prepares for Recreational Cannabis Opportunity in Israel
Dramatic Consumer Growth Predicted When Legalization Occurs Dramatic Consumer Growth Predicted When Legalization Occurs
Isracann Well Positioned for Israel's Cannabis Sector Growth in 2021
Activities in 2020 laid groundwork towards accelerated results Activities in 2020 laid groundwork towards accelerated results
Isracann Announces Launch of Early Warrant Exercise Incentive Program and Repricing
VANCOUVER, British Columbia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becomi...